The company's strategy is to develop Libiguin® up to clinical phase II, after which the company plans to partner with a major pharmaceutical company to be able to take Libiguin® to registered drug distintion and introduce Libiguin® to the global market.
The therapy area:
Erection failure (ED)
Premature ejaculation (PE)
There is a clear need for new drugs for the treatment of erectile dysfunction and premature ejaculation due to the requirement of current treatments to plan the sexual activity, disturbing side effects, lack of efficacy in certain patient groups and high cost of the drug. This is especially true for the treatment of erectile dysfunction but also premature ejaculation. Dicot's drug candidate Libiguin® is intended to be marketed for the treatment of both erectile dysfunction and premature ejaculation both individually and in combination. To the Company's knowledge, such treatment of both conditions at the same time as a preparation would be unique.
Source: Arizton 2018